AKT1 and neoplasm: Additionally, a three-way ANOVA (factor day, i.e., 1, 3, and 7, factor treatment, i.e., ipatasertib versus vehicle control, and factor HROG05 glioblastoma versus slices w/o tumor cells) with Bonferroni post hoc t-test revealed that the AKT inhibitor diminished network deflections regardless of the absence or presence of glioblastoma cells (p < 0.001).